Novavax begins U.S. phase 3 trial of coronavirus vaccine Novavax begins U.S. phase 3 trial of coronavirus vaccine
TUESDAY, DECEMBER 29, 2020
Novavax Inc. will start the final-stage trial of its coronavirus vaccine with 30,000 people in the U.S. and Mexico, opening another avenue for shots to fight the pandemic, the National Institute of Allergy and Infectious Diseases said.